This web site is part of the Business Intelligence Division of Informa PLC
Voyager Pharmaceutical Corp.
Drug Names(s): leuprolide acetate, VP 4896
Description: Memryte is an implant with sustained release of the peptide leuprolide, and analog of naturally occurring gonadotropin releasing hormone (GnRH or LH-RH). While leuprolide initially increases levels of the gonadotropins leutinizing hormone (LH) and follicle stimulating hormone (FSH), continuous administration lowers levels of these hormones. Post-menopausal women have lower estrogen levels (while there is conflicting data, this has been associated with Alzheimer's disease), resulting in increased LH. Men also can have elevated LH, though this usually occurs later in life. The companies believe abnormally elevated LH may lead to abnormal cell division and cell death in Alzheimer's.
Deal Structure: In July 2002, DURECT and Voyager entered into a development and commercialization agreement. Under the terms of the agreement, DURECT will collaborate with Voyager to develop a product using its DURIN technology to provide sustained release of leuprolide based on Voyagers patented method of treatment of Alzheimers disease. The agreement also provides Voyager with the right to commercialize the resulting product on a worldwide basis. DURECT is responsible for preclinical development, product manufacture and other specified tasks. DURECT will receive payments if certain development and regulatory milestones are achieved, and receive payments for its research and development efforts. If Memryte is commercialized, DURECT will receive royalties based on product sales.
In January 2007, DURECT announced that it had amended its development and commercialization agreement with Voyager Pharmaceutical Corporation governing Memryte, an investigational drug which utilizes DURECT's proprietary...See full deal structure in Biomedtracker
Partners: DURECT Corporation
Additional information available to subscribers only: